FDA Policy on RMAT Designations for Therapies on Clinical Hold Remains Unchanged on March 19, 2026 gene therapy Identifier Regenerative Medicine regulatory policy RMAT Study on Hold United States Food and Drug Administration +
FDA Chief Calls for Lower User Fees as PDUFA VIII Negotiations Begin on July 15, 2025 Drug Approval fee structure Mediation PDUFA VIII regulatory policy United States Food and Drug Administration user fees +